vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $23.0M, roughly 1.2× Intellia Therapeutics, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -416.2%, a 455.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 16.6%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-69.4M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
NTLA vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $26.9M |
| Net Profit | $-95.8M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | 50.0% |
| Net Margin | -416.2% | 39.2% |
| Revenue YoY | 78.8% | 16.6% |
| Net Profit YoY | 25.7% | 34.8% |
| EPS (diluted) | $-0.81 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $23.0M | $24.2M | ||
| Q3 25 | $13.8M | $25.0M | ||
| Q2 25 | $14.2M | $23.8M | ||
| Q1 25 | $16.6M | $23.1M | ||
| Q4 24 | $12.9M | $20.9M | ||
| Q3 24 | $9.1M | $20.3M | ||
| Q2 24 | $7.0M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-95.8M | $7.4M | ||
| Q3 25 | $-101.3M | $9.3M | ||
| Q2 25 | $-101.3M | $8.0M | ||
| Q1 25 | $-114.3M | $7.8M | ||
| Q4 24 | $-128.9M | $7.1M | ||
| Q3 24 | $-135.7M | $6.0M | ||
| Q2 24 | $-147.0M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -428.9% | 39.6% | ||
| Q3 25 | -808.9% | 45.8% | ||
| Q2 25 | -772.2% | 43.4% | ||
| Q1 25 | -726.6% | 43.4% | ||
| Q4 24 | -1059.9% | 30.9% | ||
| Q3 24 | -1589.0% | 36.6% | ||
| Q2 24 | -1998.6% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -416.2% | 30.7% | ||
| Q3 25 | -735.2% | 37.3% | ||
| Q2 25 | -710.8% | 33.5% | ||
| Q1 25 | -687.6% | 34.0% | ||
| Q4 24 | -1001.2% | 34.0% | ||
| Q3 24 | -1489.5% | 29.3% | ||
| Q2 24 | -2112.6% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.81 | $0.44 | ||
| Q3 25 | $-0.92 | $0.55 | ||
| Q2 25 | $-0.98 | $0.47 | ||
| Q1 25 | $-1.10 | $0.46 | ||
| Q4 24 | $-1.27 | $0.41 | ||
| Q3 24 | $-1.34 | $0.35 | ||
| Q2 24 | $-1.52 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $270.7M |
| Total Assets | $842.1M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $449.9M | $471.1M | ||
| Q3 25 | $511.0M | $232.9M | ||
| Q2 25 | $459.7M | $345.2M | ||
| Q1 25 | $503.7M | — | ||
| Q4 24 | $601.5M | $243.5M | ||
| Q3 24 | $658.1M | — | ||
| Q2 24 | $691.1M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $671.4M | $266.0M | ||
| Q3 25 | $748.4M | $255.1M | ||
| Q2 25 | $715.3M | $240.9M | ||
| Q1 25 | $779.9M | $237.9M | ||
| Q4 24 | $872.0M | $227.9M | ||
| Q3 24 | $962.6M | $235.4M | ||
| Q2 24 | $971.1M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $842.1M | $4.1B | ||
| Q3 25 | $925.3M | $4.0B | ||
| Q2 25 | $898.9M | $4.1B | ||
| Q1 25 | $986.2M | $4.0B | ||
| Q4 24 | $1.2B | $4.0B | ||
| Q3 24 | $1.2B | $4.0B | ||
| Q2 24 | $1.2B | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $12.9M |
| Free Cash FlowOCF − Capex | $-69.4M | $12.4M |
| FCF MarginFCF / Revenue | -301.6% | 46.0% |
| Capex IntensityCapex / Revenue | 0.5% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-69.3M | $46.5M | ||
| Q3 25 | $-76.9M | $11.4M | ||
| Q2 25 | $-99.6M | $13.5M | ||
| Q1 25 | $-148.9M | $9.7M | ||
| Q4 24 | $-85.2M | $39.8M | ||
| Q3 24 | $-84.8M | $12.9M | ||
| Q2 24 | $-58.2M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-69.4M | $43.2M | ||
| Q3 25 | $-76.9M | $10.8M | ||
| Q2 25 | $-99.9M | $12.8M | ||
| Q1 25 | $-149.7M | $8.3M | ||
| Q4 24 | $-86.2M | $13.7M | ||
| Q3 24 | $-86.1M | $7.0M | ||
| Q2 24 | $-59.2M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -301.6% | 178.3% | ||
| Q3 25 | -558.2% | 43.0% | ||
| Q2 25 | -701.0% | 53.6% | ||
| Q1 25 | -900.1% | 35.7% | ||
| Q4 24 | -669.4% | 65.6% | ||
| Q3 24 | -945.2% | 34.2% | ||
| Q2 24 | -850.9% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.5% | 13.7% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 1.7% | 3.2% | ||
| Q1 25 | 4.4% | 6.5% | ||
| Q4 24 | 7.6% | 125.3% | ||
| Q3 24 | 14.0% | 29.4% | ||
| Q2 24 | 14.5% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
WTBA
Segment breakdown not available.
